ESMO 2022: New Analysis in Treating Gastrointestinal and Genitourinary Cancers

The 2022 Congress of the Ecu Society for Clinical Oncology (ESMO) was once held from September 9 to 13 in Paris, France. On this podcast, David Ilson, MD, PhD, FASCO; Sumanta (Monty) Good friend, MD, FASCO; and Tian Zhang, MD, speak about highlights in gastrointestinal and genitourinary cancers introduced at this yr’s assembly.

Advances in treating gastrointestinal cancers

Dr. Ilson describes a number of research about treating more than a few varieties of gastrointestinal cancers, that are cancers that increase within the digestive tract. First, he describes the section 3 LEAP-002 medical trial, which was once inspecting whether or not including the immunotherapy drug pembrolizumab (Keytruda) to the focused remedy drug lenvatinib (Lenvima) helped other people with complex hepatocellular carcinoma of the liver are living longer. [1:58]

Subsequent, he discusses analysis in colorectal most cancers. First, he describes the section 2 NICHE-2 medical trial, which evaluated whether or not the use of a mixture of the immunotherapy medicine nivolumab (Opdivo) and ipilimumab (Yervoy) to regard in the neighborhood complex colon most cancers with a molecular function known as top microsatellite instability (MSI-H) sooner than surgical procedure lowered what number of people had most cancers discovered on the time of surgical procedure. [3:35] Then, he describes the section 3 FRESCO-2 medical trial, which studied whether or not the focused remedy drug fruquintinib may assist other people with metastatic colorectal most cancers who had won all different usual therapies are living longer. [5:55] In any case, he describes 2 promising focused remedy medicine for complex colon most cancers mentioned on the assembly, sotorasib (Lumakras) and adagrasib, which paintings by way of focused on KRAS G12C mutations. [7:24]

Then, Dr. Ilson describes the section 2 DESTINY-Gastric02 medical trial, which was once seeing whether or not the focused remedy drug trastuzumab deruxtecan (Enhertu) helped shrink the most cancers and, if that is so, for the way lengthy in other people with HER2-positive abdomen most cancers that had no longer been stopped by way of earlier remedy with the focused remedy drug trastuzumab (to be had as a biosimilar). [8:46]

New analysis in genitourinary cancers

Dr. Sumanta (Monty) Pal and Dr. Tian Zhang

Dr. Good friend and Dr. Zhang speak about a number of research in genitourinary cancers, that are cancers within the urinary tract and in male reproductive organs. First, they speak about 4 research in localized kidney most cancers, all of that have been finding out whether or not more than a few therapies helped decrease the danger of recurrence after surgical procedure to take away the most cancers [12:16]:

  • The section 3 PROSPER medical trial, which was once finding out nivolumab given each sooner than and after surgical procedure in other people with renal cellular carcinoma

  • The section 3 IMmotion010 medical trial, which was once finding out the immunotherapy drug atezolizumab (Tecentriq) in other people with renal cellular carcinoma who had won surgical procedure and had an greater possibility of the most cancers coming again

  • The section 3 CheckMate914 medical trial, which was once comparing the mix of nivolumab with ipilimumab given after surgical procedure to other people with renal cellular carcinoma with a top possibility of the most cancers returning

  • An replace from the KEYNOTE-564 section 3 medical trial, which was once finding out pembrolizumab given after surgical procedure in other people with renal cellular carcinoma with a top possibility of the most cancers returning

Additionally in kidney most cancers, they speak about the section 3 COSMIC-313 medical trial, which examined whether or not including the angiogenesis inhibitor cabozantinib (Cometriq) to nivolumab and ipilimumab in other people with in the past untreated, complex renal cellular carcinoma helped lengthen most cancers enlargement. [17:37]

Then, they speak about a find out about in treating complex bladder most cancers. The section 1b/2 EV-103 medical trial explored whether or not the mix of the focused remedy drug enfortumab vedotin (Padcev) with pembrolizumab helped shrink the tumors in other people with in the neighborhood complex or metastatic urothelial carcinoma who may no longer obtain cisplatin chemotherapy. [21:16]

In any case, they speak about 2 research in treating prostate most cancers. First, they speak about the section 3 PRESTO medical trial, which was once comparing whether or not intensified hormonal remedy helped prevent prostate-specific antigen (PSA) ranges from expanding after surgical procedure for prostate most cancers. [23:46] Then, they speak about the section 3 PROpel medical trial, which was once seeing whether or not including the focused remedy drug olaparib (Lynparza) to the hormonal remedy abiraterone (Zytiga) helped gradual or prevent the expansion of metastatic castration-resistant prostate most cancers. [25:37]

Dr. Ilson is an attending doctor and member at Memorial Health center and a professor of drugs at Weill Cornell Clinical Faculty. He’s a 2022 Most cancers.Internet Strong point Editor for Gastrointestinal Cancers. Dr. Good friend is co-director of Town of Hope’s Kidney Most cancers Program and is the pinnacle of the kidney and bladder most cancers illness workforce on the establishment. He’s the 2022 Most cancers.Internet Affiliate Editor for Genitourinary Cancers. Dr. Zhang is an Affiliate Professor of Inside Drugs at UT Southwestern Clinical Heart and is a clinical oncologist on the Harold C. Simmons Complete Most cancers Heart. She is a 2022 Most cancers.Internet Strong point Editor for Genitourinary Most cancers.

Disclosure data for this podcast’s audio system will also be discovered of their particular person biographies connected to within the paragraph above.

Used to be this podcast helpful? Please subscribe, price, and assessment Most cancers.Internet Podcasts anywhere you pay attention to podcasts. This prerecorded podcast will also be listened to on-line or downloaded in your laptop. A transcript may be to be had. For more info, seek advice from the Most cancers.Internet podcast web page.

Most cancers.Internet podcasts are edited for period and content material.

Share Us

Inquiry Now